OBJECTIVE: to evaluate the main factors associated with long-term persistence in fully paid lipid-lowering treatment. METHODS: We selected 628 moderately hypercholesterolemic subjects (M: 307; F: 311, mean age 59 ± 9 years old), to whom we firstly prescribed a statin (N. 397) or different kinds of lipid-lowering nutraceuticals (N. 231). Then, depending on their will, patients took brand statin (N. 194) or generic statins (N. 203). RESULTS: The main determinants of long-term persistence in therapy are female sex (OR 1.21, 95%CI 1.08-1.42), family history of early cardiovascular disease (OR 1.31, 95%CI 1.13-1.49), baseline LDL-C (OR 1.19, 95%CI 1.02-1.33) and treatment with nutraceuticals versus statins (OR 1.29, 95%CI 1.14-1.38). Persistence appears not to be influenced by patient's age, smoking habit, adverse events during treatment, and estimated cardiovascular risk. CONCLUSION: Among self-paying patients with mild hyperlipidemia, medication persistence is highest among those taking nutraceuticals, followed by brand statins, followed by generic statins.
Cicero AF, Derosa G, Parini A, Baronio C, Borghi C. (2014). Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments. ATHEROSCLEROSIS, 235, 81-83 [10.1016/j.atherosclerosis.2014.04.016].
Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments.
CICERO, ARRIGO FRANCESCO GIUSEPPE;BORGHI, CLAUDIO
2014
Abstract
OBJECTIVE: to evaluate the main factors associated with long-term persistence in fully paid lipid-lowering treatment. METHODS: We selected 628 moderately hypercholesterolemic subjects (M: 307; F: 311, mean age 59 ± 9 years old), to whom we firstly prescribed a statin (N. 397) or different kinds of lipid-lowering nutraceuticals (N. 231). Then, depending on their will, patients took brand statin (N. 194) or generic statins (N. 203). RESULTS: The main determinants of long-term persistence in therapy are female sex (OR 1.21, 95%CI 1.08-1.42), family history of early cardiovascular disease (OR 1.31, 95%CI 1.13-1.49), baseline LDL-C (OR 1.19, 95%CI 1.02-1.33) and treatment with nutraceuticals versus statins (OR 1.29, 95%CI 1.14-1.38). Persistence appears not to be influenced by patient's age, smoking habit, adverse events during treatment, and estimated cardiovascular risk. CONCLUSION: Among self-paying patients with mild hyperlipidemia, medication persistence is highest among those taking nutraceuticals, followed by brand statins, followed by generic statins.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
